Cranmer, Lee D.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 245

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentBioactive Compounds and Antitumor Agents

Cited by 155

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

Pollack, S. M., Redman, M. W., Baker, K. K., Wagner, M. J., Schroeder, B. A., Loggers, E. T., Trieselmann, K., Copeland, V. C., Zhang, S., Black, G., et al. (2020) · JAMA Oncology

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 142

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismBioactive Compounds and Antitumor Agents

Cited by 113

Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial

Seo, Y. D., Lu, H., Black, G., Smythe, K., Yu, Y., Hsu, C., Ng, J., Hermida de Viveiros, P., Warren, E. H., Schroeder, B. A., et al. (2023) · JAMA Oncology

Sarcoma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 31

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

Chesney, J., Collichio, F., Andtbacka, R. H. I., Puzanov, I., Glaspy, J., Milhem, M., Hamid, O., Cranmer, L., Saenger, Y., Ross, M., et al. (2016) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 15